Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy

Transplantation Proceedings

Volumn 38, Issue 10, 2006, Pages 3552-3555

  Neff, G W ^a   Kemmer, N ^a   Zacharias, V C ^a   Kaiser, T ^a   Duncan, C ^a   McHenry, R ^a   Jonas, M ^a   Novick, D ^a   Williamson, C ^a   Hess, K ^a   Thomas, M ^a   Buell, J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTULOSE; RIFAXIMIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEMOGRAPHY; DRUG COST; DRUG DOSE TITRATION; ECONOMIC EVALUATION; EMERGENCY HEALTH SERVICE; FEMALE; HEALTH CARE COST; HEPATIC ENCEPHALOPATHY; HOSPITAL CARE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LIVER DISEASE; LIVER GRAFT; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; COSTS AND COST ANALYSIS; FEMALE; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMANS; LACTULOSE; LENGTH OF STAY; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RIFAMYCINS;

EID: 33845383261     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.10.107     Document Type: Article

References (27)

1. Als-Nielsen B., Gluud L.L., and Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328 (2004) 1046
2. Festi D., et al. Treatment of hepatic encephalopathy with non-absorbable antibiotics. Ital J Gastroenterol 24 suppl 2 (1992) 14
3. [Branched-chain amino acids and their therapeutic use]. Internist (Berl) suppl (1992) 1
4. Shawcross D.L., et al. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis 20 (2005) 169
5. Ahboucha S., and Butterworth R.F. Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis 19 4 (2004) 331
6. Kardel T., and Gips C.H. Alpha-ketoglutarmate, glutamate antagonism and GABA depletion-clues to the pathogenesis of hepatic encephalopathy?. Neth J Med 17 (1974) 37
7. Funovics J.M., and Fischer J.E. Brain energy metabolism and alterations of transmitter profiles in acute hepatic coma. J Neural Transm Suppl (1978) 61
8. Zeneroli M.L., et al. Metabolism and brain uptake of gamma-aminobutyric acid in galactosamine-induced hepatic encephalopathy in rats. J Neurochem 38 (1982) 1219
9. Ferenci P., et al. Overestimation of serum concentrations of gamma-aminobutyric acid in patients with hepatic encephalopathy by the gamma-aminobutyric acid-radioreceptor assay. Hepatology 8 (1988) 69
10. Zeneroli M.L., et al. Management of hepatic encephalopathy: role of rifaximin. Chemotherapy 51 suppl 1 (2005) 90
11. Williams R., and Bass N. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord 5 suppl 1 (2005) 10
12. Maddrey W.C. Role of antibiotics in the management of hepatic encephalopathy. Rev Gastroenterol Disord 5 suppl 1 (2005) 3
13. Maddrey W.C. Role of antibiotics in hepatic encephalopathy: current status and future directions. Rev Gastroenterol Disord 5 suppl 1 (2005) 1-2
14. Cordoba J., Minguez B., and Vergara M. Treatment of hepatic encephalopathy. Lancet 365 (2005) 1384 (author reply 1385)
15. Blei A.T. Treatment of hepatic encephalopathy. Lancet 365 (2005) 1383 (author reply 1383)
16. Morgan M.Y. The treatment of chronic hepatic encephalopathy. Hepatogastroenterology 38 (1991) 377
17. Shawcross D., and Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 365 (2005) 431
18. Atipo-Ibara B.I., et al. [Cost of of hospital management of cirrhoses and its complications at the University Hospital of Brazzaville]. Med Trop (Mars) 64 (2004) 50
19. Scarpignato C., and Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51 suppl 1 (2005) 36
20. Testa R., et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 11 (1985) 387
21. Williams R., et al. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 12 (2000) 203
22. Venturini I., et al. Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. Drugs Exp Clin Res 31 (2005) 161
23. Paik Y.H., et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 46 (2005) 399
24. Riggio O., et al. Intractable hepatic encephalopathy after tips with polytetrafluoroethylene-covered stent-graft. Scand J Gastroenterol 38 (2003) 570
25. Miglio F., et al. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 13 (1997) 593
26. Di Piazza S., et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 23 (1991) 403
27. Bucci L., and Palmieri G.C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 13 (1993) 109